Meloxicam.

Q1 Pharmacology, Toxicology and Pharmaceutics Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-12 DOI:10.1016/bs.podrm.2019.10.006
Nasr Y Khalil, Khalid F Aldosari
{"title":"Meloxicam.","authors":"Nasr Y Khalil,&nbsp;Khalid F Aldosari","doi":"10.1016/bs.podrm.2019.10.006","DOIUrl":null,"url":null,"abstract":"<p><p>Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.006","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2019.10.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 4

Abstract

Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Meloxicam。
美洛昔康是一种非甾体抗炎药(NSAID),是一种奥昔康衍生物:4-羟基-2-甲基- n -(5-甲基-2-噻唑基)- 2h -1,2-苯并噻唑-3-羧酰胺1,1-二氧化。它是环氧化酶-2 (COX-2)的选择性抑制剂。它用于类风湿关节炎,骨关节炎急性加重,强直性脊柱炎和青少年特发性关节炎的管理。单次口服剂量为7.5mg,必要时增加至每日最大15mg(老年人7.5mg)。它也可以通过直肠栓剂给予,剂量与口服剂量相似。据报道,美洛昔康的副作用与非甾体类抗炎药(NSAIDs)相似,如腹痛、贫血和水肿。严重胃肠道(GI)不良事件的风险也增加,包括溃疡和出血。本简介旨在讨论和解释美洛昔康的物理特性、专有和非专有名称。它还包括制备方法,热学和光谱行为,分析方法,药代动力学,代谢,排泄和药理学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Profiles of drug substances, excipients, and related methodology
Profiles of drug substances, excipients, and related methodology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
13.10
自引率
0.00%
发文量
4
期刊最新文献
Avanafil: A comprehensive drug profile. Deferasirox: A comprehensive drug profile. Duvelisib: A comprehensive profile. Ponatinib: A comprehensive drug profile. Regorafenib: A comprehensive drug profile.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1